Clinical Trial Update: Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A in PD-GBA Patients [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating AFFITOPE PD01A in Parkinson's disease patients with GBA mutations was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• AFFITOPE PD01A (PD01A)

Snippet

Sponsor: Affiris AG | Conditions: Parkinson's Disease | Phase 1 | Status: WITHDRAWN